Impact on quality of life from multi-modality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multi-modality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
Authors
Taylor, SallyTsim, S
Navani, N
Baldwin, D
Woolhouse, I
Edwards, J
Grundy, S
Robson, J
Rhodes, S
Burnside, N
Blackhall, Fiona H
Faivre-Finn, Corinne
Yorke, Janelle
Evison, M
Affiliation
Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2021-07
Metadata
Show full item recordCitation
Taylor, Sally, Tsim, S ,Navani, N, Baldwin, D, Woolhouse, I, Edwards, J, Grundy, S, Robson, J, Rhodes, S Burnside, N, Blackhall, Fiona H,Faivre-Finn, Corinne, Yorke, Janelle, Evison, M. Impact on quality of life from multi-modality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multi-modality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial) Lung Cancer. 2022 Jul; 8(1): e000846.Journal
Lung CancerDOI
10.1136/bmjresp-2020-000846PubMed ID
34266853Additional Links
https://dx.doi.org/10.1136/bmjresp-2020-000846Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjresp-2020-000846
Scopus Count
Collections
Related articles
- Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
- Authors: Evison M, Edwards J, McDonald F, Popat S
- Issue date: 2020 Aug
- Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study).
- Authors: Lim E, Batchelor T, Shackcloth M, Dunning J, McGonigle N, Brush T, Dabner L, Harris R, Mckeon HE, Paramasivan S, Elliott D, Stokes EA, Wordsworth S, Blazeby J, Rogers CA, VIOLET Trialists
- Issue date: 2019 Oct 14
- Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer.
- Authors: Bograd AJ, Vallières E
- Issue date: 2020 Jun
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
- Authors: Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C, Song H
- Issue date: 2017 Dec 16
- Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer.
- Authors: Van Schil PE, Yogeswaran K, Hendriks JM, Lauwers P, Faivre-Finn C
- Issue date: 2017 Jun